For example, fedratinib, an innovative JAK inhibitor that simultaneously targets the activities of JAK2 and Fms-like tyrosine kinase 3 (FLT3) with crucial effects on the survival and proliferation of primitive hematopoietic progenitor cells, has been approved as an oral treatment for intermediate or high-risk myelofibrosis.560–562. This evidence concerns the gene FLT3 and myelofibrosis.